All studies have shown that PCSK9 mAbs (evolocumab or alirocumab) with or without statin therapy significantly reduce LDLc in patients with hypercholesterolemia and heterozygous familial hypercholesterolemia (31, 32, 49, 70). The gene discussed is PCSK9; the disease is Hypercholesterolemia.